Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fimbrial antigens are proteinaceous surface appendages (fimbriae or pili) found primarily on Gram-negative bacteria such as Escherichia coli and Salmonella spp[1][4][5]. They are typically much shorter and thinner than bacterial flagella and occur in high numbers on the cell surface. Each fimbrial structure is primarily composed of repeating pilin protein subunits and terminates in specialized adhesive proteins called adhesins, which enable specific binding to glycoprotein receptors on host epithelial cells[3][5][8][9]. This binding is a critical first step in bacterial colonization, allowing pathogens to establish infection at mucosal surfaces (such as the gut, urinary tract, or respiratory tract)[4][7]. Fimbrial antigens are highly immunogenic, able to stimulate strong host immune responses, and are important in the development of vaccines aimed at preventing bacterial infections. Classification schemes for fimbrial antigens are based on morphology, serology, and genetic sequence, with notable subtypes including type 1, F, K88, K99, and colonization factor antigens (CFA/I, CFA/II, etc.)[1][2]. Because their structure shows significant antigenic variation, fimbriae help bacteria evade host immunity, posing a challenge for vaccine development[2][7]. Fimbriae also play roles in aggregation of bacteria and possibly motility. They are not cellular receptors, enzymes, or ion channels but represent a distinct family of bacterial adhesin/antigenic structures. In summary, fimbrial antigens are a diverse group of bacterial surface proteins critical for host adhesion, pathogenesis of infection, and immune recognition, with significant roles as targets for preventive therapies such as vaccines.
Anti-adhesive vaccines or antibodies: block fimbrial adhesion to the host Antibody-mediated opsonization and clearance Inhibition of colonization factor function Experimental agents may destabilize fimbrial assembly
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fimbrial antigen.